Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
Clinical trial NCT01229644 · TERMINATED
Trial details
- NCT number
- NCT01229644
- Sponsor
- Arog Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-04-01
- Primary completion
- 2012-06-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.